JAK/STAT signaling
JAK/STAT signaling inhibitors are compounds that disrupt the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway, which is involved in cytokine signaling, cell growth, and immune response. These inhibitors are important tools in studying the regulation of this pathway and its role in various diseases, including cancers, immune disorders, and inflammatory conditions. JAK/STAT inhibitors are also being developed as targeted therapies for these diseases. At CymitQuimica, we provide a wide selection of high-quality JAK/STAT signaling inhibitors to support your research in molecular biology, oncology, and immunology.
Subcategories of "JAK/STAT signaling"
Products of "JAK/STAT signaling"
Sort by
Ifidancitinib
CAS:Ifidancitinib (ATI-50002) is a JAK kinase 1/3 inhibitor used to study autoimmune diseases.Formula:C20H18FN5O3Purity:98.05%Color and Shape:SolidMolecular weight:395.39Pim-1/2 kinase inhibitor 1
CAS:Orally active Pim-1/2 inhibitor blocks kinase phosphorylation; used in prostate cancer research.Formula:C11H9NO3SPurity:99.89%Color and Shape:SolidMolecular weight:235.26JAK-IN-10
CAS:JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.Formula:C20H18FN5O3SPurity:98.88%Color and Shape:SolidMolecular weight:427.45Ref: TM-T13571
1mg87.00€5mg177.00€10mg260.00€25mg429.00€50mg605.00€100mg815.00€500mg1,624.00€1mL*10mM (DMSO)188.00€JAK kinase-IN-1
CAS:JAK kinase-IN-1 (Example 1) functions as a potent inhibitor targeting the JAK family, which includes TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32Formula:C17H19F2N7OSPurity:98%Color and Shape:SolidMolecular weight:407.44Tofacitinib Citrate
CAS:Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).Formula:C22H28N6O8Purity:99.19% - 99.75%Color and Shape:SolidMolecular weight:504.49ITK inhibitor 2
CAS:ITK inhibitor 2 is a interleukin-2-inducible T-cell kinase (ITK) inhibitor , with an IC50 of 2 nM.Formula:C25H33N5O2Color and Shape:SolidMolecular weight:435.56TAK-901
CAS:TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among othersFormula:C28H32N4O3SPurity:97.38% - 99.1%Color and Shape:SolidMolecular weight:504.64(2R)-Octyl-α-hydroxyglutarate
CAS:(2R)-Octyl-α-hydroxyglutarate ((2R)-Octyl-2-HG) is a D-isomer 2-Hydroxyglutarate modified form.Formula:C13H24O5Color and Shape:SolidMolecular weight:260.33Ilginatinib hydrochloride
CAS:Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.Formula:C21H21ClFN7Purity:99.55%Color and Shape:SolidMolecular weight:425.89Ref: TM-T12266L2
1mg77.00€5mg165.00€10mg240.00€25mg408.00€50mg562.00€100mg800.00€200mg1,074.00€1mL*10mM (DMSO)177.00€G5-7
CAS:G5-7 is an oral JAK2 inhibitor targeting EGFR/STAT3 phosphorylation with potential for glioma research.Formula:C22H19F2NO3Purity:97.30%Color and Shape:SolidMolecular weight:383.39Ref: TM-T8742
1mg50.00€5mg97.00€10mg145.00€25mg259.00€50mg374.00€100mg523.00€200mg710.00€1mL*10mM (DMSO)105.00€2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
CAS:2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity and physicochemical properties.Formula:C16H13Cl2N3O2Purity:98.77%Color and Shape:SolidMolecular weight:350.2RO495
CAS:RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assaysFormula:C17H14Cl2N6OPurity:97.94%Color and Shape:SolidMolecular weight:389.24Ref: TM-T22416
1mg64.00€2mg87.00€5mg117.00€10mg183.00€25mg354.00€50mg520.00€100mg702.00€200mg944.00€1mL*10mM (DMSO)140.00€JAK-IN-5 hydrochloride
CAS:JAK-IN-5 hydrochloride is a JAK inhibitor [1].Formula:C27H32ClFN6OColor and Shape:SolidMolecular weight:511.03Cenacitinib
CAS:Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.Formula:C19H19F2N7O3Color and Shape:SolidMolecular weight:431.40JAK/HDAC-IN-2
JAK/HDAC-IN-2, a potent 2-amino-4-phenylaminopyrimidine dual-target inhibitor, effectively suppresses JAK1/2 and HDAC3/6 at nanomolar concentrations.Formula:C28H38N6O5SPurity:98%Color and Shape:SolidMolecular weight:570.7SGI-1776
CAS:SGI-1776 (Pim-Kinase Inhibitor IX) has been used in trials studying the treatment of Prostate Cancer, Non-Hodgkins Lymphoma, and Relapsed/Refractory Leukemias.Formula:C20H22F3N5OPurity:100% - 99.84%Color and Shape:SolidMolecular weight:405.42Nimucitinib
CAS:Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.Formula:C25H26F2N6O2Purity:98.71%Color and Shape:SoildMolecular weight:480.51Ref: TM-T67907
1mg96.00€2mg139.00€5mg227.00€10mg354.00€25mg653.00€50mg938.00€100mg1,454.00€500mg2,822.00€JAK2-IN-6
CAS:JAK2-IN-6: A potent JAK2-specific inhibitor (IC50=22.86μg/mL), blocks JAK2 signaling, has anticancer properties, and is inactive against JAK1/3.Formula:C14H10ClN3OS2Purity:99.38%Color and Shape:SolidMolecular weight:335.83JAK3/BTK-IN-2
CAS:JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor.Formula:C25H32N8O2Purity:99.64%Color and Shape:SolidMolecular weight:476.57WP1066
CAS:WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3.Formula:C17H14BrN3OPurity:98.92% - 99.73%Color and Shape:SolidMolecular weight:356.22
